Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jul 21;25(3):368-372.
doi: 10.5935/1518-0557.20200077.

Efficacy of daily GnRH agonist for luteal phase support following GnRH agonist triggered ICSI cycles versus conventional strategy: A Randomized controlled trial

Saghar Salehpour  1 , Leila Nazari  1 , Sedighe Hosseini  1 , Elham Azizi  2 , Nasrin Borumandnia  3 , Teibeh Hashemi  1
Affiliations
Randomized Controlled Trial

Efficacy of daily GnRH agonist for luteal phase support following GnRH agonist triggered ICSI cycles versus conventional strategy: A Randomized controlled trial

Saghar Salehpour et al. JBRA Assist Reprod. .

Abstract

Objective: The use of gonadotropin-releasing hormone agonist (GnRHa) as an alternative for human chronic gonadotropin (hCG) trigger has potential benefits, but the optimal luteal phase support (LPS) following GnRHa trigger remains to be elucidated. We aimed to investigate a new strategy (daily GnRH agonist for LPS following GnRH agonist trigger) as an alternative for the conventional approach to the patients undergoing intracytoplasmic sperm injection (ICSI).

Methods: In this randomized controlled trial study, 44 ICSI patients were randomly assigned into two groups: group 1, patients received standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS); group 2, patients received a dose of GnRHa (0.2 mg) for ovulation trigger and subcutaneous injection of GnRHa bid (0.2 mg) for LPS.

Results: The pregnancy, miscarriage, and live birth rates for the patients undergoing LPS following the GnRHa trigger were similar to those of patients undergoing the standard strategy.

Conclusions: We showed that a daily subcutaneous injection of GnRHa for LPS following the GnRHa trigger can be successfully performed as an alternative to the standard strategy, with comparable pregnancy and live birth rates in ICSI patients.

Keywords: GnRH agonist; intracytoplasmic sperm injection; live birth; luteal phase; pregnancy rate.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, Omer Y, Sheena L, Carmon N, Ben-David G. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril. 2016;106:330–333. doi: 10.1016/j.fertnstert.2016.04.004. - DOI - PubMed
    1. Bar-Hava I, Blueshtein M, Herman HG, Omer Y, David GB. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles. Fertil Steril. 2017;107:130–135.e1. doi: 10.1016/j.fertnstert.2016.10.011. - DOI - PubMed
    1. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril. 1989;52:398–400. doi: 10.1016/S0015-0282(16)60906-8. - DOI - PubMed
    1. Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod Biomed Online. 2016;32:274–285. doi: 10.1016/j.rbmo.2015.12.007. - DOI - PubMed
    1. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14:236–242. doi: 10.1016/S1043-2760(03)00075-4. - DOI - PubMed

Publication types

Substances

LinkOut - more resources